Cargando…

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients

BACKGROUND: End-stage kidney disease substantially increases the risk of severe COVID-19. However, despite early robust immunogenicity of the mRNA-SARS-CoV-2 vaccination in patients with hemodialysis, the longevity of humoral response in this high-risk population is still unknown. METHODS: A prospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agur, Timna, Ben-Dor, Naomi, Herman-Edelstein, Michal, Steinmetz, Tali, Lichtenberg, Shelly, Schneider, Shira, Yahav, Dafna, Rozen-Zvi, Benaya, Zingerman, Boris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990786/ https://www.ncbi.nlm.nih.gov/pubmed/35402451 http://dx.doi.org/10.3389/fmed.2022.781888

Ejemplares similares

SARS-CoV-2 antibody dynamics among kidney transplant recipients 3 months after BNT162b2 vaccination: a prospective cohort study
por: Yelin, Dana, et al.
Publicado: (2022)

Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study
por: Yahav, Dafna, et al.
Publicado: (2022)

BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
por: Herman-Edelstein, Michal, et al.
Publicado: (2022)

BNT162b2 vaccine effectiveness in chronic kidney disease patients—an observational study
por: Bielopolski, Dana, et al.
Publicado: (2022)

The Humoral Response to SARS-CoV-2 Vaccine in Hemodialysis Patients Is Correlated with Nutritional Status
por: Jacobson-Naftali, Merav, et al.
Publicado: (2023)

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study
por: Rozen-Zvi, Benaya, et al.
Publicado: (2021)

Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
por: Yahav, Dafna, et al.
Publicado: (2021)

The Association Between Exposure to Low Magnesium Blood Levels After Renal Transplantation and Cardiovascular Morbidity and Mortality
por: Lahav, Itay, et al.
Publicado: (2021)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Precautions after vaccinating immunosuppressed patients with mRNA-based vaccines against SARS-CoV-2: does one size fit all?
por: Tau, Noam, et al.
Publicado: (2021)

Nephrologists’ Perspectives on Home Dialysis Utilization: A National Survey From Israel
por: Goldman, Shira, et al.
Publicado: (2023)

Effect of Acetazolamide on Obesity-Induced Glomerular Hyperfiltration: A Randomized Controlled Trial
por: Zingerman, Boris, et al.
Publicado: (2015)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
por: Mavrovouniotis, Ilias, et al.
Publicado: (2023)

Oxidative Stress-Induced DNA Damage and Repair in Human Peripheral Blood Mononuclear Cells: Protective Role of Hemoglobin
por: Gafter-Gvili, Anat, et al.
Publicado: (2013)

Changes in Serum Creatinine May Cause Hypoglycemia among Non-Critically Ill Patients Admitted to Internal Medicine Units
por: Zingerman, Boris, et al.
Publicado: (2022)

Microalbuminuria After Kidney Transplantation Predicts Cardiovascular Morbidity
por: Bielopolski, Dana, et al.
Publicado: (2021)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis
por: Li, Tingting, et al.
Publicado: (2022)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
por: Speer, Claudius, et al.
Publicado: (2021)

Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
por: Einbinder, Yael, et al.
Publicado: (2022)

Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2022)

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
por: Massarweh, Amir, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study
por: GIUBELAN, LUCIAN-ION, et al.
Publicado: (2022)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Change in Kidney Function and 2-Year Mortality After Transcatheter Aortic Valve Replacement
por: Witberg, Guy, et al.
Publicado: (2021)

Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
por: Berar-Yanay, Noa, et al.
Publicado: (2021)

Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients
por: Housset, Pierre, et al.
Publicado: (2022)

Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis
por: Dekervel, Marine, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
por: Di Noia, V., et al.
Publicado: (2022)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
por: Rammauro, Florencia, et al.
Publicado: (2022)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7qomcb8e5gtle69obtd5recsq7